Compare Neurocrine Biosciences Inc (NBIX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Procter & Gamble Co — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while Procter & Gamble Co trades at $150.16 (market cap $343.34B). The key difference: Procter & Gamble Co is far larger — about 23.5× Neurocrine Biosciences Inc's market cap, and Procter & Gamble Co pays a 2.95% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Procter & Gamble Co for 131 Days on average.
| NBIX | PG | |
|---|---|---|
Market Cap | $14.60B | $343.34B |
Volume | 1,075,694 | 8,662,344 |
Sector | Health | Consumer Staples |
52-Week High | $185.50 | $167.18 |
52-Week Low | $123.10 | $138.10 |
Typical Hold Time | 23 Days | 131 Days |
Enterprise Value | $14.61B | $369.18B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Procter & Gamble (PG) trades at $147.82, down 0.4% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $1.88. Strong fundamentals include $84.28B revenue, 18.44% net margin, and robust cash flow generation. Recent developments include a WNBA partnership and a dividend declaration of $1.09 payable in August 2026.
PG offers stable growth with premium valuation metrics (P/E 22.33, P/S 4.11) supported by strong brand equity and dividend consistency. Risks include premium valuation concerns amid modest growth outlook and competitive pressures. Analyst consensus is bullish with a $160.13 price target, though near-term upside may be limited given current price proximity to the lower target range.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
